CD274 and non-small cell lung carcinoma: The findings of KEYNOTE-024 led to the FDA approval of pembrolizumab as a first-line treatment for selected patients with metastatic EGFR/ALK wild-type NSCLC and with PD-L1 TPS ≥ 50% (71).